Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 5/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523734 | 0.98 | GPR84 (0.43) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL21645392 | 0.98 | GPR84 (0.43) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL27139253 | 0.98 | GPR84 (0.43) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL6541852 | 0.93 | CAMK2A (0.39) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL24703880 | 0.91 | ALDH1A1 (0.42) | ALDH1A1KDM5ALMNAALOX5KDM4A | |
| SCHEMBL29991123 | 0.89 | ALDH1A1 (0.41) | ALDH1A1KDM5ALMNAKDM4AKDM4C | |
| SCHEMBL22205611 | 0.86 | LMNA (0.44) | ALDH1A1KDM5ALMNAALOX5KDM4A | |
| SCHEMBL933822 | 0.84 | — | — | |
| SCHEMBL13552252 | 0.83 | PAOX (0.41) | ALDH1A1KDM5ALMNAALOX5KDM4A | |
| SCHEMBL1713084 | 0.83 | ALDH1A1 (0.52) | GPR84FFAR1FFAR4ALDH1A1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| WO-2022047014-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20170334831-A1 | Kinetic resolution of racemic hydroxy ester via asymmetric catalytic hydrogenation and application thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156831-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156831-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | GPR84 4736/4885FFAR1 4746/4885FFAR4 4830/4885 |
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | GPR84 1936/4885FFAR1 3856/4885FFAR4 4056/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | GPR84 4736/4885FFAR1 4746/4885FFAR4 4830/4885 |
| US-20100168243-A1 | Renin Inhibitors | ACE, REN, DNPEP | GPR84 1936/4885FFAR1 3856/4885FFAR4 4056/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | GPR84 4736/4885FFAR1 4746/4885FFAR4 4830/4885 |
| US-20170334831-A1 | Kinetic resolution of racemic hydroxy ester via asymmetric catalytic hydrogenation and application thereof | CYP8B1, CYP3A5, HRH4 | GPR84 973/4885FFAR1 1008/4885FFAR4 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.